Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

avanos medical - AVNS

AVNS

Close Chg Chg %
11.38 0.03 0.26%

Closed Market

11.41

+0.03 (0.26%)

Volume: 341.80K

Last Updated:

Dec 26, 2025, 3:59 PM EDT

Trade Now

Company Overview: avanos medical - AVNS

AVNS Key Data

Open

$11.29

 Day Range

11.29 - 11.45

52 Week Range

9.30 - 17.68

 Market Cap

$529.18M

Shares Outstanding

46.42M

 Public Float

44.70M

Beta

1.09

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$10.18

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

528.99K

  

AVNS Performance

1 Week
 
 -2.23%
 
1 Month
 
 -2.81%
 
3 Months
 
 -3.06%
 
1 Year
 
 -28.33%
 
5 Years
 
 -75.13%
 

AVNS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About avanos medical - AVNS

Avanos Medical, Inc. is a medical technology company, which engages in delivering clinically superior medical device solutions and products to healthcare providers and patients. The company was founded on February 25, 2014 and is headquartered in Alpharetta, GA.

AVNS At a Glance

Avanos Medical, Inc.
5405 Windward Parkway
Alpharetta, Georgia 30004-3894
Phone 1-844-428-2667 Revenue 687.80M
Industry Medical Specialties Net Income -392,100,000.00
Sector Health Technology 2024 Sales Growth 2.154%
Fiscal Year-end 12 / 2025 Employees 2,227
View SEC Filings

AVNS Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.065
Price to Book Ratio 0.883
Price to Cash Flow Ratio 7.27
Enterprise Value to EBITDA 9.296
Enterprise Value to Sales 1.156
Total Debt to Enterprise Value 0.214

AVNS Efficiency

Revenue/Employee 308,845.981
Income Per Employee -176,066.457
Receivables Turnover 5.179
Total Asset Turnover 0.483

AVNS Liquidity

Current Ratio 2.371
Quick Ratio 1.535
Cash Ratio 0.649

AVNS Profitability

Gross Margin 55.438
Operating Margin 5.816
Pretax Margin -58.636
Net Margin -57.008
Return on Assets -27.141
Return on Equity -37.418
Return on Total Capital -38.68
Return on Invested Capital -32.16

AVNS Capital Structure

Total Debt to Total Equity 20.543
Total Debt to Total Capital 17.042
Total Debt to Total Assets 14.746
Long-Term Debt to Equity 18.093
Long-Term Debt to Total Capital 15.01
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Avanos Medical - AVNS

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
744.60M 820.00M 673.30M 687.80M
Sales Growth
+4.17% +10.13% -17.89% +2.15%
Cost of Goods Sold (COGS) incl D&A
382.40M 370.00M 293.60M 306.50M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
38.30M 47.70M 43.50M 45.50M
Depreciation
21.60M 22.00M 19.20M 20.30M
Amortization of Intangibles
16.70M 25.70M 24.30M 25.20M
COGS Growth
+17.95% -3.24% -20.65% +4.39%
Gross Income
362.20M 450.00M 379.70M 381.30M
Gross Income Growth
-7.27% +24.24% -15.62% +0.42%
Gross Profit Margin
+48.64% +54.88% +56.39% +55.44%
2021 2022 2023 2024 5-year trend
SG&A Expense
318.10M 368.00M 314.70M 341.30M
Research & Development
32.30M 30.60M 27.20M 26.20M
Other SG&A
285.80M 337.40M 287.50M 315.10M
SGA Growth
-0.50% +15.69% -14.48% +8.45%
Other Operating Expense
- - - -
-
Unusual Expense
43.40M 4.50M 47.50M 440.10M
EBIT after Unusual Expense
700.00K 77.50M 17.50M (400.10M)
Non Operating Income/Expense
8.40M (2.30M) (10.40M) 9.00M
Non-Operating Interest Income
200.00K 1.20M 2.90M 5.10M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
3.30M 10.00M 15.00M 12.20M
Interest Expense Growth
-78.85% +203.03% +50.00% -18.67%
Gross Interest Expense
3.30M 10.00M 15.00M 12.20M
Interest Capitalized
- - - -
-
Pretax Income
5.80M 65.20M (7.90M) (403.30M)
Pretax Income Growth
+109.59% +1,024.14% -112.12% -5,005.06%
Pretax Margin
+0.78% +7.95% -1.17% -58.64%
Income Tax
600.00K 14.70M 2.00M (17.00M)
Income Tax - Current - Domestic
(4.40M) 16.50M 6.10M 13.60M
Income Tax - Current - Foreign
1.50M 1.90M 4.00M 5.30M
Income Tax - Deferred - Domestic
3.40M (3.30M) (6.80M) (35.00M)
Income Tax - Deferred - Foreign
100.00K (400.00K) (1.30M) (900.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
5.20M 50.50M (9.90M) (386.30M)
Minority Interest Expense
- - - -
-
Net Income
5.20M 50.50M (9.90M) (386.30M)
Net Income Growth
+119.12% +871.15% -119.60% -3,802.02%
Net Margin Growth
+0.70% +6.16% -1.47% -56.16%
Extraordinaries & Discontinued Operations
- - (51.90M) (5.80M)
-
Discontinued Operations
- - (51.90M) (5.80M)
-
Net Income After Extraordinaries
5.20M 50.50M (61.80M) (392.10M)
Preferred Dividends
- - - -
-
Net Income Available to Common
5.20M 50.50M (61.80M) (392.10M)
EPS (Basic)
0.1081 1.0768 -1.3262 -8.5239
EPS (Basic) Growth
+119.00% +896.11% -223.16% -542.73%
Basic Shares Outstanding
48.10M 46.90M 46.60M 46.00M
EPS (Diluted)
0.107 1.0676 -1.3262 -8.5239
EPS (Diluted) Growth
+118.80% +897.76% -224.22% -542.73%
Diluted Shares Outstanding
48.60M 47.30M 46.60M 46.00M
EBITDA
82.40M 129.70M 108.50M 85.50M
EBITDA Growth
-27.59% +57.40% -16.35% -21.20%
EBITDA Margin
+11.07% +15.82% +16.11% +12.43%

Snapshot

Average Recommendation HOLD Average Target Price 14.00
Number of Ratings 1 Current Quarters Estimate 0.25
FY Report Date 12 / 2025 Current Year's Estimate 0.90
Last Quarter’s Earnings 0.22 Median PE on CY Estimate N/A
Year Ago Earnings 1.35 Next Fiscal Year Estimate 0.95
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 1 1 1
Mean Estimate 0.25 0.23 0.90 0.95
High Estimates 0.25 0.23 0.90 0.95
Low Estimate 0.25 0.23 0.90 0.95
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 0 0 0
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Hold Hold Hold

Insider Actions for Avanos Medical - AVNS

Date Name Shares Transaction Value
Sep 10, 2025 John J. Hurley Principal Accounting Officer 11,364 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $12.66 per share 143,868.24
May 15, 2025 Michael C. Greiner Former Interim CEO 204,493 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $12.43 per share 2,541,847.99
May 15, 2025 Michael C. Greiner Former Interim CEO 200,019 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $12.43 per share 2,486,236.17
Mar 12, 2025 Sigfrido Delgado SVP, Operations 27,819 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Kerr Holbrook SVP, Chief Commercial Officer 98,860 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Kerr Holbrook SVP, Chief Commercial Officer 49,088 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Sigfrido Delgado SVP, Operations 21,914 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Mojirade Amanda James SVP, General Counsel 41,199 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Mojirade Amanda James SVP, General Counsel 88,218 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 7, 2025 Joseph F. Woody 443,036 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $15.13 per share 6,703,134.68
Mar 7, 2025 John J. Hurley Principal Accounting Officer 10,101 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $15.13 per share 152,828.13
Mar 7, 2025 John J. Hurley Principal Accounting Officer 10,134 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $15.13 per share 153,327.42
Mar 7, 2025 Mojirade Amanda James SVP, General Counsel 73,648 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $15.13 per share 1,114,294.24
Mar 7, 2025 Joseph F. Woody 434,852 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $15.13 per share 6,579,310.76
Mar 7, 2025 Joseph F. Woody 453,203 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 7, 2025 Michael C. Greiner Interim CEO 203,545 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $15.13 per share 3,079,635.85
Mar 7, 2025 Kerr Holbrook SVP, Chief Commercial Officer 89,047 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $15.13 per share 1,347,281.11
Jan 7, 2025 Indrani L. Franchini Director 16,820 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 7, 2025 Gary D. Blackford Director 71,593 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 7, 2025 Julie A. Shimer Director 62,093 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Avanos Medical in the News